N | ATG | PTCY | Test p value |
---|---|---|---|
1452 | 174 | Â | |
Follow-up | |||
 Median time (IQR) mo | 33.2 (17.6–52.7) | 20.5 (6.9–32.6) | < 0.001 |
Age at allo-HSCT | |||
 Median (range) [IQR] | 56 (18.1–77.5) [44.3–62.6] | 46 (18–74.2) [34.7–59.3] | < 0.001 |
Year allo-HSCT | |||
 Median (range) [IQR] | 2014 (2010–2017) | 2016 (2010–2017) | < 0.001 |
Time diagnosis to allo-HSCT | |||
 Median (range) [IQR] | 5.4 (1.5–17.7) [4.4–6.6] | 4.7 (1.8–17.9) [3.8–7.7] | 0.1 |
AML | |||
 De novo | 1206 (83.06%) | 161 (92.53%) | 0.001 |
 secAML | 246 (16.94%) | 13 (7.47%) | |
Cytogenetics (MRC) | |||
 Good | 59 (4.06%) | 4 (2.3%) | 0.19 |
 Interm | 740 (50.96%) | 80 (45.98%) | |
 Poor | 291 (20.04%) | 35 (20.11%) | |
 NA/failed | 362 (24.93%) | 55 (31.61%) | |
Conditioning regimen | |||
 MAC | 687 (47.31%) | 76 (43.68%) | 0.36 |
 RIC | 765 (52.69%) | 98 (56.32%) | |
Gaft cell type | |||
 BM | 143 (9.85%) | 18 (10.34%) | 0.84 |
 PBSC | 1309 (90.15%) | 156 (89.66%) | |
Kanofsky performance score | |||
 < 90 | 331 (24.68%) | 29 (16.76%) | 0.02 |
 ≥ 90 | 1010 (75.32%) | 144 (83.24%) | |
 Missing | 111 | 1 | |
Patient sex | |||
 Male | 759 (52.27%) | 98 (56.32%) | 0.31 |
 Female | 693 (47.73%) | 76 (43.68%) | |
Female donor-male recipient | 165 (11.41%) | 26 (14.94%) | 0.17 |
Patient CMV serostatus | |||
 Negative | 499 (34.92%) | 43 (25.15%) | 0.011 |
 Positive | 930 (65.08%) | 128 (74.85%) | |
 Missing | 23 | 3 | |
Engraftement | |||
 Graft failure | 12 (0.83%) | 2 (1.16%) | 0.65 |
 Engrafted | 1432 (99.17%) | 170 (98.84%) | |
 Missing | 8 | 2 |